Hemophilia Archives - Hematology Advisor

Hemophilia

FDA Approves Wilate for Hemophilia A in Adult and Adolescent Patients

The Food and Drug Administration (FDA) has approved Wilate (von Willebrand Factor/Coagulation Factor VIII Complex [Human]; Octapharma) for routine prophylaxis to reduce the frequency of bleeding episodes and on-demand treatment and control of bleeding episodes in patients with hemophilia A.  The approval was based on data from the prospective, open-label, multicenter phase 3 trial that…

Investigational Therapy for Hemophilia A Granted Orphan Drug Designation

The Food and Drug Administration (FDA) has granted Orphan Drug designation to SIG-001 (Sigilon Therapeutics) for the treatment of hemophilia A. SIG-001 utilizes Sigilon’s Shielded Living Therapeutics platform to implant engineered human cells to produce stable blood plasma levels of factor VIII. The cells are also shielded by Sigilon’s proprietary Afibromer biomaterials matrix that minimizes…

Next post in Bleeding Disorders